Suchergebnisse
Filter
9 Ergebnisse
Sortierung:
Questionable assumptions mar modelling of Kenya home‐based testing campaigns
In: Journal of the International AIDS Society, Band 22, Heft 1
ISSN: 1758-2652
HIV, 95‐95‐95 and the allocative efficiency fallacy: why treating everyone makes sense from a humanitarian, clinical, economic and disease control perspective
In: Journal of the International AIDS Society, Band 21, Heft 10
ISSN: 1758-2652
Confronting TB/HIV in the era of increasing anti‐TB drug resistance
In: Journal of the International AIDS Society, Band 11, Heft 1, S. 6-6
ISSN: 1758-2652
HIV associated TB is a major public health problem. In 2006, it was estimated that there were over 700,000 people who suffered from HIV associated TB, of whom about 200, 000 have died. The burden of HIV associated TB is greatest in Sub‐Saharan Africa where the TB epidemic is primarily driven by HIV. There has been steady progress made in reducing the burden of HIV in TB patients with an increasing number of TB patients tested for HIV and provided with cotrimoxazole preventive therapy (CPT) and anti‐retroviral treatment (ART). Less progress is being made to reduce the burden of TB in people living with HIV. The number of HIV infected persons reported to have been screened for TB was less than 1% while Isoniazid preventive therapy was reported to have been provided to less than 0.1% of eligible persons in 2006. A major push is urgently needed to accelerate the implementation of three important interventions. The three are Intensified TB Screening (ICF) among people living with HIV, the provision of Isoniazid Preventive Therapy (IPT) and TB Infection Control(IC). These interventions are best carried out by HIV control programmes which should therefore be encouraged to take greater responsibility in implementing these interventions.
Le VIH, la santé et votre communauté: un guide pour l'action
In: Etudes et recherches, No. 238-239
Le livre est un guide pour les agents de santé à travers le monde, notamment dans les zones où les ressources médicales sont peu nombreuses. Conçu comme un manuel pour les gens confrontés à la pandémie du VIH dans leurs communautés, il a été écrit de façon à être très accessible à ceux qui n'ont aucune connaissance médicale ou technique et sans formation préalable dans le domaine de la prévention du VIH et du suivi médical de ceux qui vivent avec le SIDA. Les thèmes vont de la biologie du virus à l'élaboration de programmes de prévention, de l'épidémiologie de la maladie à la rédaction des propositions de subvention. Les auteurs discutent explicitement des facteurs des risques d'infection et suggèrent des méthodes utiles pour expliquer et aider les gens à changer de comportement. (DÜI-Sbd)
World Affairs Online
Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis
In: Bulletin of the World Health Organization: the international journal of public health = Bulletin de l'Organisation Mondiale de la Santé, Band 90, Heft 2, S. 128-138C
ISSN: 1564-0604
Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV
In: Bulletin of the World Health Organization: the international journal of public health = Bulletin de l'Organisation Mondiale de la Santé, Band 88, Heft 4, S. 253-259
ISSN: 1564-0604
Highly active antiretroviral treatment for the prevention of HIV transmission
In: Journal of the International AIDS Society, Band 13, Heft 1, S. 1-1
ISSN: 1758-2652
In 2007 an estimated 33 million people were living with HIV; 67% resided in sub‐Saharan Africa, with 35% in eight countries alone. In 2007, there were about 1.4 million HIV‐positive tuberculosis cases. Globally, approximately 4 million people had been given highly active antiretroviral therapy (HAART) by the end of 2008, but in 2007, an estimated 6.7 million were still in need of HAART and 2.7 million more became infected with HIV.Although there has been unprecedented investment in confronting HIV/AIDS ‐ the Joint United Nations Programme on HIV/AIDS estimates $13.8 billion was spent in 2008 ‐ a key challenge is how to address the HIV/AIDS epidemic given limited and potentially shrinking resources. Economic disparities may further exacerbate human rights issues and widen the increasingly divergent approaches to HIV prevention, care and treatment.HIV transmission only occurs from people with HIV, and viral load is the single greatest risk factor for all modes of transmission. HAART can lower viral load to nearly undetectable levels. Prevention of mother to child transmission offers proof of the concept of HAART interrupting transmission, and observational studies and previous modelling work support using HAART for prevention. Although knowing one's HIV status is key for prevention efforts, it is not known with certainty when to start HAART.Building on previous modelling work, we used an HIV/AIDS epidemic of South African intensity to explore the impact of testing all adults annually and starting persons on HAART immediately after they are diagnosed as HIV positive. This theoretical strategy would reduce annual HIV incidence and mortality to less than one case per 1000 people within 10 years and it would reduce the prevalence of HIV to less than 1% within 50 years. To explore HAART as a prevention strategy, we recommend further discussions to explore human rights and ethical considerations, clarify research priorities and review feasibility and acceptability issues.
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria
In recent years, evidence has accumulated regarding the ability of HAART to prevent HIV transmission. Early supportive evidence was derived from observational, ecological and population-based studies. More recently, a randomized clinical trial showed that immediate use of HAART led to a 96% decrease in HIV transmission events within HIV serodiscordant heterosexual couples. However, the generalizability of the effect of HAART, and the population-level impact on HIV transmission continues to generate substantial debate. We, therefore, conducted a review of the evidence regarding the preventive effect of HAART on HIV transmission within the context of the Bradford Hill criteria for causality. Taken together, we find the accumulated evidence supporting HIV treatment as prevention meets each of the Bradford Hill criteria for causality. We conclude that the opportunity cost of inaction while waiting for additional evidence on the generalizability of effect in other risk groups is too high. Efforts should be redoubled to mobilize the financial capital and political will to optimize implementation of HIV Treatment as Prevention strategies on a wide scale.
BASE